Headquartered in Cambridge, MA, Alnylam is leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of people with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a clinically validated approach for the treatment of diseases with high unmet need. Alnylam’s first U.S. FDA-approved RNAi therapeutic is ONPATTRO™ (patisiran) available in the U.S. for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Additionally, Alnylam has three investigational medicines in late-stage development. For more information visit www.alnylam.com.